Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer)
The company has an internal once-weekly peptide (NNC-06620419, Phase 2 started October 2025), a ~$2B license on United Laboratories' UBT-251 (Phase 1b/2a running, 19.7% weight loss at 24 weeks in the Chinese Phase 2), a $2.2B collaboration with Septerna for small-molecule oral GPCR agonists including a triple, and a long-running in-house discovery pipeline
Preclinical studies in diet-induced obese (DIO) mice showed that once-weekly administration of the PEGylated GLP-1R/GcgR co-agonist for 1 month dramatically lowered body weight, compared with vehicle treatment [17]
Non-GLP-1 Weight-Loss Strategies for Sustained Affordability GLP-1 medications are tools, not cures
Developed with Harvard-trained dermatologists and clinically tested on all skin tones and types
5-HTP, a precursor to serotonin, supports enteric nervous system function
